Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
AbbVie (NYSE: ABBV) reported positive topline results from two replicate Phase 3 studies of upadacitinib 15 mg once daily in adults and adolescents with non-segmental vitiligo, announcing that both studies met co-primary endpoints at week 48 for T-VASI 50 (≥50% total-body repigmentation) and F-VASI 75 (≥75% facial repigmentation).
Key efficacy: T-VASI 50 rates were 19.4% and 21.5% on drug versus 5.9% placebo; F-VASI 75 rates were 25.2% and 23.4% on drug versus 5.9% and 6.9% placebo; F-VASI 50 was 48.1% and 43.4% versus 12.7% and 12.9% placebo. Safety was consistent with known profiles: common TEAEs included upper respiratory infection, acne and nasopharyngitis; no new safety signals, no adjudicated MACE or VTE.
Use in non-segmental vitiligo is not approved and has not been evaluated by regulators.
Allergan Aesthetics (NYSE:ABBV) renewed its seven-year partnership with Girls Inc. on Oct 28, 2025
Key initiatives include an Allergan Medical Institute (AMI) Atlanta Training Center visit with a panel of local women healthcare providers and the SkinSpirit Gives campaign inviting client donations from Nov 1–Nov 15, 2025. Donations will fund STEM programming, mentorship, and career exploration for more than 120,000 girls across 75 affiliates in the U.S. and Canada. The announcement emphasizes mentorship and resources to increase female representation in STEM, noting women hold 18% of U.S. STEM jobs and 55% of girls express STEM interest.
Allergan Aesthetics (NYSE: ABBV) announced the 2025 grant recipients of The Confidence Project by BOTOX® Cosmetic. Twenty entrepreneurs completed a 12-week Boostcamp and each received a $20,000 grant. Since inception, the program has awarded more than $1 million in grants. Winners attended a virtual Celebration & Community Summit with networking, expert breakout sessions, and a conversation with beauty entrepreneur Deepica Mutyala.
The 2025 class spans consumer, beauty, food & beverage, and wellness founders; winners will be featured on @botoxcosmetic channels and at botoxcosmetic.com/real-impact.
AbbVie (NYSE: ABBV) reported topline Phase 3b/4 SELECT-SWITCH results showing RINVOQ (upadacitinib) 15 mg once daily was superior to HUMIRA (adalimumab) 40 mg biweekly at Week 12 in adults with moderate-to-severe rheumatoid arthritis who failed a prior TNF inhibitor.
Key results: 43.3% on upadacitinib achieved low disease activity (DAS28-CRP≤3.2) vs 22.4% on adalimumab (p<0.001); 28.4% vs 14.5% achieved remission (DAS28-CRP<2.6) (p<0.001). Safety was consistent with prior studies with no new risks identified in the 12-week period.
AbbVie (NYSE: ABBV) completed its acquisition of Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin, on Oct 17, 2025.
Bretisilocin is described as a novel, short-acting 5-HT2A receptor agonist and serotonin releaser currently in Phase 2 clinical development for moderate-to-severe major depressive disorder (MDD). AbbVie said the compound is next‑generation and designed to address development challenges seen with classic psychedelic therapies, and that the company plans to accelerate its development within AbbVie’s psychiatry pipeline.
AbbVie (NYSE: ABBV) announced that on October 13, 2025 the U.S. FDA approved a supplemental NDA updating the indication for RINVOQ (upadacitinib) to treat adults with moderately to severely active ulcerative colitis and Crohn's disease.
The updated label permits RINVOQ to be used prior to tumor necrosis factor (TNF) blockers for patients for whom TNF blockers are clinically inadvisable and allows use after the patient has received at least one approved systemic therapy. The change expands prescribing options for physicians treating inflammatory bowel disease.
The release reiterates RINVOQ safety considerations, including risks of serious infections, increased risk of death and major cardiovascular events in people age 50+ with ≥1 heart disease risk factor, certain cancers, blood clots, serious allergic reactions, and gastrointestinal tears.
AbbVie (NYSE: ABBV) will present new clinical data at the ESMO 2025 Congress (October 17–21, 2025) on its antibody-drug conjugate portfolio, highlighting telisotuzumab adizutecan (Temab-A), ABBV-706, and other ADC programs.
Key findings include Temab-A: ORR 46% in 100 MET-amplified solid tumor patients (NSCLC 69%, GEA 71%); Temab-A+bevacizumab ORR 26.7% in heavily pretreated CRC vs 0% with trifluridine/tipiracil+bev; Temab-A in PDAC ORR 24% overall (40% in prior gemcitabine–nab-paclitaxel subgroup). Observed grade ≥3 TEAEs included anemia and neutropenia across studies. ABBV-706 data show ctDNA clearance linked to higher PFS and OS and support ongoing first-line combination study.
Allergan Aesthetics, an AbbVie company (NYSE: ABBV) announced SkinMedica's reimagined packaging and the new HA5® Hydra Collagen Water Burst Moisturizer on Oct 9, 2025. The redesign features a refreshed logo, luxe copper accents, intuitive navigation, and sustainability upgrades: 90% of packaging components by weight recyclable, 100% of secondary cartons recyclable, and a 71% reduction in landfill waste (~550,000 lbs annually). Product launches include HA5 moisturizer (up to 24-hour hydration, 25% moisture boost after one application), TNS Advanced+ serum dual-pump, and phased rollout across the portfolio over the next year. HA5 moisturizer retails at $78 and is available online and via licensed physicians and spas.
AbbVie (NYSE: ABBV) reported positive topline results from the Phase 2 ELATE trial of onabotulinumtoxinA (BOTOX) for upper limb essential tremor on Oct 6, 2025. The study met its primary endpoint at week 18: TREDS-R total unilateral score change was -2.61 for onabotulinumtoxinA vs -1.61 for placebo (p=0.029). The trial also met all six secondary endpoints. Safety was consistent with the known profile of onabotulinumtoxinA; the most common adverse event was localized, mostly mild-to-moderate muscular weakness (24.5% on active vs 2.3% placebo). Results will be presented at the International Congress of Parkinson's Disease and Movement Disorders on Oct 8, 2025. BOTOX for essential tremor is not approved by the FDA or other regulators.
AbbVie (NYSE:ABBV) has scheduled its third-quarter 2025 financial results announcement for Friday, October 31, 2025, before market opening. The company will conduct a live earnings conference call at 8 a.m. Central time.
Investors can access the webcast through AbbVie's Investor Relations website at investors.abbvie.com. An archived version of the presentation will be made available later the same day.
FAQ
What is the current stock price of Abbvie (ABBV)?
What is the market cap of Abbvie (ABBV)?
